Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82370 | 1.00 | NFE2L2 (0.48) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL1082918 | 0.81 | NFE2L2 (0.48) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL7542717 | 0.79 | NFE2L2 (0.46) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL7774660 | 0.79 | NFE2L2 (0.46) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL809698 | 0.79 | NFE2L2 (0.42) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL5704309 | 0.78 | NFE2L2 (0.50) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL73286 | 0.78 | AHR (0.50) | NFE2L2CYP2A6FBP1ALOX5PTGS1 | |
| SCHEMBL8442224 | 0.78 | NFE2L2 (0.50) | NFE2L2RELACA1CYP2A6FBP1 | |
| SCHEMBL73285 | 0.78 | AHR (0.50) | NFE2L2CYP2A6FBP1ALOX5PTGS1 | |
| SCHEMBL19452718 | 0.76 | NFE2L2 (0.48) | NFE2L2RELACA1CYP2A6FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101362724-A | Tetramethylpyrazine acidamides derivates, preparation method and medicament composition and application | UNIV SHANDONG (CN) | 2009-02-11 | — | — | CN | claimed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-102838625-A | Tetrahydropyridothiazole compounds, preparation method thereof, pharmaceutical composition containing same and application thereof | SHANGHAI INST MATERIA MEDICA | 2012-12-26 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| CN-101362724-B | Tetramethylpyrazine acidamides derivates, preparation method and medicament composition and application | UNIV SHANDONG | 2011-03-16 | — | — | CN | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| CN-101362724-A | Tetramethylpyrazine acidamides derivates, preparation method and medicament composition and application | UNIV SHANDONG (CN) | 2009-02-11 | — | — | CN | disclosed |
| US-7429633-B2 | Brush-form alternative copolymer and process for producing the same | SHISEIDO COMPANY, LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20070203303-A1 | Brush-Form Alternative Copolymer And Process For Producing The Same | SHISEIDO COMPANY, LTD. (JP) | 2007-08-30 | — | — | US | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0199982-B1 | AZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PLANT GROWTH-REGULATING COMPOSITIONS | BASF Aktiengesellschaft (DE) | 1991-04-03 | — | — | EP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| US-4874861-A | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0199982-A2 | Azole derivatives, process for their preparation and plant growth-regulating compositions | BASF Aktiengesellschaft (DE) | 1986-11-05 | — | — | EP | disclosed |
| EP-0183212-A2 | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4115398-A | CARDIOVASCULAR DISORDERS | KOWA COMPANY LTD. (JP) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | NFE2L2 3996/4885RELA 4079/4885CA1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.